)
Pressure BioSciences (PBIO) investor relations material
Pressure BioSciences Status Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Operational updates and relocation
Relocation to a new facility with 90% manufacturing labs has improved operational efficiency and reduced costs by consolidating R&D and manufacturing, increasing space by 20% while lowering lease expenses by 20-30%.
The move caused significant delays, including late regulatory approvals and lab setup, impacting financial filings and operations, but the company is now fully functional and ready for business.
The new facility enables future growth and in-house manufacturing, shifting from a virtual to a manufacturing-focused company.
Financial and compliance status
The 2023 10-K annual report was filed late due to relocation delays, with a commitment to avoid future late filings; the Q filing is targeted for June 30.
Management acknowledges the inconvenience to stakeholders and is working to restore compliance and maintain it going forward.
Core business and technology focus
Pressure Cycling Technology (PCT) and BaroFold remain important, with ongoing sales and service, but focus has shifted to UltraShear technology due to its market potential.
UltraShear enables precise, stable nano-emulsions, significantly improving absorption of oil-based actives, as demonstrated in preclinical studies with CBD and THC.
UltraShear's applications span pharmaceuticals, nutraceuticals, cosmetics, agrochemicals, and food and beverage, targeting multi-billion dollar markets.
)
)
)
)
)
)
)
)